BIO 2026: AltruBio believes that its PSGL-1, a T-cell checkpoint targeting antibody, could be a "ceiling raiser" in the I&I space
- 1 day ago
- 1 min read
Chair and CEO Judy Chou describes the science behind the target (this is the company's second generation molecule), and discusses the current clinical program in UC. She believes they have a "best in disease outcome" medicine and says they have talked to all the key players in I&I regarding a potential collaboration.
Coverage brought to you by











.png)